Johnson Investment Counsel Inc. Raises Stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Johnson Investment Counsel Inc. raised its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 34.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 29,428 shares of the medical instruments supplier's stock after buying an additional 7,603 shares during the quarter. Johnson Investment Counsel Inc. owned approximately 0.13% of LeMaitre Vascular worth $2,469,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its stake in shares of LeMaitre Vascular by 1.4% during the fourth quarter. Geode Capital Management LLC now owns 550,260 shares of the medical instruments supplier's stock worth $50,711,000 after purchasing an additional 7,737 shares during the last quarter. Northern Trust Corp increased its stake in LeMaitre Vascular by 5.1% in the 4th quarter. Northern Trust Corp now owns 327,815 shares of the medical instruments supplier's stock valued at $30,205,000 after buying an additional 15,843 shares during the period. Price T Rowe Associates Inc. MD increased its stake in LeMaitre Vascular by 0.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 284,779 shares of the medical instruments supplier's stock valued at $26,240,000 after buying an additional 1,680 shares during the period. Envestnet Asset Management Inc. raised its position in LeMaitre Vascular by 7.0% during the 4th quarter. Envestnet Asset Management Inc. now owns 259,429 shares of the medical instruments supplier's stock worth $23,904,000 after buying an additional 16,886 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of LeMaitre Vascular by 2.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 195,752 shares of the medical instruments supplier's stock worth $18,037,000 after acquiring an additional 4,241 shares during the period. Hedge funds and other institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Price Performance

LeMaitre Vascular stock traded up $1.42 during mid-day trading on Tuesday, reaching $84.80. The company had a trading volume of 132,835 shares, compared to its average volume of 169,728. The stock's 50-day simple moving average is $83.82 and its 200-day simple moving average is $89.14. LeMaitre Vascular, Inc. has a 1 year low of $71.42 and a 1 year high of $109.58. The company has a debt-to-equity ratio of 0.48, a current ratio of 16.49 and a quick ratio of 13.83. The company has a market capitalization of $1.92 billion, a P/E ratio of 42.83, a P/E/G ratio of 2.16 and a beta of 0.83.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.02). The firm had revenue of $59.87 million during the quarter, compared to analysts' expectations of $57.61 million. LeMaitre Vascular had a net margin of 19.96% and a return on equity of 13.53%. The business's revenue for the quarter was up 12.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.44 earnings per share. On average, equities analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, May 29th. Investors of record on Thursday, May 15th were given a $0.20 dividend. The ex-dividend date was Thursday, May 15th. This represents a $0.80 annualized dividend and a dividend yield of 0.94%. LeMaitre Vascular's dividend payout ratio is presently 40.40%.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Barrington Research lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Oppenheimer lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Finally, Lake Street Capital increased their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $97.83.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 4,399 shares of the stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $85.10, for a total transaction of $374,354.90. Following the sale, the chief executive officer now owns 1,827,003 shares in the company, valued at approximately $155,477,955.30. This represents a 0.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders have sold 100,000 shares of company stock valued at $8,556,857. Insiders own 9.50% of the company's stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.